Excitement Over MS Stem Cell Transplant 'Game Changer' Data
An international trial has demonstrated that HSCT was more effective than standard drugs for people with highly active relapsing-remitting multiple sclerosis. Also a one-off transplant compared to lifelong therapy has considerable cost-saving implications.
You may also be interested in...
With Alexion's Soliris already approved, and Viela's inebilizumab within touching distance of an FDA green light, Roche is highlighting the safety profile of its investigational neuromyelitis optica spectrum disorder drug satralizumab.
Susanne Schaffert tells Scrip that policies of prioritizing coronavirus treatment to the detriment of cancer care was a worrying move that is negatively impacting survival and mortality.
Lynparza has received the green light from the FDA for advanced prostate cancer, its fourth tumor type, and while it may not be the first PARP inhibitor to be approved for this indication, analysts are expecting the drug to lead the class.